Brain and Spine Tumors Clinical Trials

Chemotherapy and Autotransplantation for Patients with Newly Diagnosed Anaplastic Oligodendroglioma
Aims: The purpose of this study is to investigate the effectiveness of temozolomide followed by high dose busulfan and thiotepa and a stem cell rescue in participants with an anaplastic oligodendroglioma or an anaplastic oligoastrocytoma.
Principal Investigator: Nina A. Paleologos, MD
IRB Approval Number: EH03-189
Funding Source: Integrated Therapeutics, Inc.
Contact: Please call 847.570.2025 with questions regarding the study.
Open to Enrollment: Yes

Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas
Aims: The purpose of this study is to compare the effects of adding temozolomide to radiation with the hope that the combination of two therapies will improve the outcome of treatment for participants with low-grade gliomas.
Principal Investigator: Nina A. Paleologos, MD
IRB Approval Number: EH10-241
Funding Source: N/A
Contact: Please call 847.570.2025 with questions regarding the study.
Open to Enrollment: Yes

GLIOGENE International Case-Control Study of Malignant Glioma
Aims: The goal of this epidemiological study is to learn about the possible factors that may lead to a higher risk of developing a brain tumor such as genetic and environmental factors, including exposure to radiation and/or chemicals. This study is looking for both individuals who have been diagnosed with a glioma, and visitors to the Kellogg Center who have never been diagnosed with cancer.
Principal Investigator: Ryan T. Merrell, MD
IRB Approval Number: EH08-327
Funding Source: National Cancer Institute
Contact: Please call 847.570.2025 with questions regarding the study.
Open to Enrollment: Yes

An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Aims: The purpose of this research study is to confirm that the addition of Rindopepimut/GM-CSF to Adjuvant Temozolomide improves the overall survival in participants with newly diagnosed EGFRvIII-positive glioblastoma who have undergone resection.
Principal Investigator: Nina A. Paleologos, MD
IRB Approval Number: EH11-311
Funding Source: Celldex Therapeutics
Contact: Please call 847.570.2025 with questions regarding the study.
Open to Enrollment: Yes

A Phase II Study of Rindopepimut/GM-CSF in Patients with Relapsed EGFRvIII-Positive Glioblastoma
Aims: The purpose of this research study is to evaluate whether the addition of the investigational vaccine rindopepimut to bevacizumab can improve the progression free survival of patients with relapsed EGFRvIII positive glioblastoma.
Principal Investigator: Nina A. Paleologos, MD
IRB Approval Number: EH12-095
Funding Source: Celldex Therapeutics
Contact: Please call 847.570.2025 with questions regarding the study.
Open to Enrollment: Yes